Stifel's commentary also mentioned that C.H. Robinson has been considered a "show-me story," indicating that the market has been waiting for proof of the company's performance and strategy ...

Stifel upgraded C.H. Robinson (CHRW) to Buy from Hold with an unchanged price target of $113. The company reported “solid” Q4 results and the ...

The firm’s CEO cited a “very competitive” recruiting market in 2024, but forecasts a better 2025 as longer-term efforts pay ...

Stifel Nicolaus analyst Ian Gillies maintained a Buy rating on Badger Infrastructure Solutions (BADFF – Research Report) today and set a price ...

The natural beauty of West Virginia will be celebrated both musically and visually in the Wheeling Symphony Orchestra’s upcoming performance, “Nature. Beauty.” Set for 2 p.m., Feb. 8, at the Capitol ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $125.6, a high estimate of $135.00, and a low estimate of $115.00. This upward trend is evident, ...

Fintel reports that on January 30, 2025, Stifel upgraded their outlook for Edwards Lifesciences (NYSE:EW) from Hold to Buy. Analyst Price Forecast Suggests 12.29% Upside As of January 28, 2025, the ...

CEO Mattias Perjos said surgical perfusion has “been a struggling category” since an FDA consent decree forced Getinge off the U.S. market in 2015.

Learn more about whether SEI Investments Company or Stifel Financial Corp. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Stifel chief executive Ron Kruszewski said surging markets have forced firms to be particularly choosy about which advisors ...

Learn more about whether Intercontinental Exchange, Inc. or Stifel Financial Corp. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.